Accelerated partial breast irradiation in early breast cancer (APBI)
Abstract
-
References
1. Polgár C, Strnad V, Major T. Brachytherapy for partial breast irradiation: the European experience. Semin Radiat Oncol 2005;15:116–22.
2. Vicini FA, Arthur DW. Breast brachytherapy: North American experience. Semin Radiat Oncol 2005;15:108–15.
3. Clarke DH, Lé MG, Sarrazin D, Lacombe MJ, Fontaine F, Travagli JP, et al. Analysis of local regional relapses in patients with early breast cancers treated by excision and radiotherapy. Experience of the Institute Gustave Roussy. Int J Radiat Oncol Biol Phys 1985;11:137–45.
4. Van Limbergen E, van der Bogaert W, van der Shueuren E, Rijnders A, et al. Tumor excision and radiotherapy as primary treatment of breast cancer: analysis of patient and treatment parameters and local control. Radiother Oncol 1987;8:1–9.
5. Njeh CF, Saunders MW, Langton CM. Accelerated Partial Breast Irradiation (APBI): A review of available techniques. Radiation Oncology 2010,5:90
6. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology ( ASTRO) Int J Radiat Oncol Biol Phys 2009;74:987-1001.
7. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378–1387.
8. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259–3265.
9. Chao KK, Vicini FA, Wallace M, Mitchell C, Chen P, Ghilezan M, et al. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irra- diation: The William Beaumont hospital experience. Int J Radiat Oncol Biol Phys 2007;69:32–40.
10. Vicini F, Beitsch PD, Quiet CA, Keleher AJ, Garcia D, Snider HC Jr, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 2008;112:758–766.
11. Ribeiro GG, Magee B, Swindell R, Harris M, Banerjee SS.The Christie Hospital breast conservation trial: An update at 8 years from inception. Clin Oncol (R Coll Radiol) 1993;5:278–283.
12. Ribeiro GG, Dunn G, Swindell R, Harris M, Banerjee SS. Conservation of the breast using two different radiotherapy techniques: Interim report of a clinical trial. Clin Oncol (R Coll Radiol) 1990;2:27–34.
13. Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose- rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2006;64:489–495.
14. Kaufman SA, DiPetrillo TA, Price LL, Midle JB, Wazer DE. Long-term out- come and toxicity in a Phase I/II trial using high-dose-rate mul- ticatheter interstitial brachytherapy for T1/T2 breast cancer. Brachytherapy 2007;6:286–292.
15. Evans SB, Kaufman SA, Price LL, Cardarelli G, Dipetrillo TA, Wazer DE. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: Incidence, pathologic anatomy, and contributing factors. Int J Radiat Oncol Biol Phys 2006;65:333–339.
16. Shah NM, Tenenholz T, Arthur D, DiPetrillo T, Bornstein B, Cardarelli G. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: Factors that affect toxicity and cosmesis. Cancer 2004;101: 727–734.
17. Wazer DE, Berle L, Graham R, Chung M, Rothschild J, Graves T, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys 2002;53:889–897.
18. Wazer DE, Lowther D, Boyle T, Ulin K, Neuschatz A, Ruthazer R, et al. Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2001;50:107–111.
19. Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264-73
20. Antonucci JV, Wallace M, Goldstein NS, Kestin L, Chen P, Benitez P, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole- breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 2009;74:447–52.
21. Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95–17. Int J Radiat Oncol Biol Phys 2008;72:467–73.
22. Johansson B, Karlsson L, Liljegren G, Hardell L, Persliden J. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1–T2 breast cancer: first long time results from a clinical study. Radiother Oncol 2009;90:30–5.
23. Patel RR, Christensen ME, Hodge C, Adkison JB, Das RK. Clinical outcome analysis in ‘‘high- risk” versus ”low-risk” patients eligible for National Surgical Adjuvant Breast and Bowel B-39/Radiation Therapy Oncology Group 0413 trial: five-year results. Int J Radiat Oncol Biol Phys 2008;70:970–3.
24. Polgár C, Sulyok Z, Fodor J, Orosz Z, Major T, Takácsi-Nagy Z, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I–II study and initial findings of a randomized phase III trial. J Surg Oncol 2002;80:121–8.
25. Polgár C, Major T, Fodor J, Németh G, Orosz Z, Sulyok Z, et al. HDR brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 2004;60:1173–81.
26. Polgár C, Strnad V, Major T. Brachytherapy for partial breast irradiation: the European experience. Semin Radiat Oncol 2005;15:116–22.
27. Polgár C, Fodor J, Major T, Németh G, Lövey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma – 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007;69:694–702.
28. Polgár C, Major T, Lövey K, et al. Hungarian experience on partial breast irradiation versus whole breast irradiation: 12-year results of a phase II trial and updated results of a randomized study. Brachytherapy 2008;7:91–2 [Abstract].
29. Polgár C, Major T. Current status and perspectives of brachytherapy for breast cancer. Int J Clin Oncol 2009;14:7–24.
30. Strnad V, Ott OJ, Hildebrandt G, et al. Partial breast irradiation using multicatheter interstitial brachytherapy for early breast cancer: Results of the German–Austrian multicenter Phase II trial. Brachytherapy 2009;8:107 [Abstract].
31. Polgár C, Fodor J, Major T, Orosz Z, Németh G. The role of boost irradiation in the conservative treatment of stage I–II breast cancer. Pathol Oncol Res 2001;7:241–50.
32. Polgár C, Fodor J, Orosz Z, Major T, Takácsi-Nagy Z, Mangel LC. Electron and high dose rate brachytherapy boost in the conservative treatment of stage I–II breast cancer: first results of the randomized Budapest boost trial. Strahlenther Onkol 2002;178:615–23.
33. Polgár C, Fodor J, Orosz Z, T Major, Z Sulyok, Z Takacsi-Nagy. Electron and brachytherapy boost in the conservative treatment of stage I–II breast cancer: 5-year results of the randomized Budapest boost trial. Radiother Oncol 2002;64:S15 [Abstract].
34. Clarke DH, Lé MG, Sarrazin D, Lacombe MJ, Fontaine F, Travagli JP, Analysis of local regional relapses in patients with early breast cancers treated by excision and radiotherapy. Experience of the Institute Gustave Roussy. Int J Radiat Oncol Biol Phys 1985;11:137–45
35. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A. Five-year results: the initial clinical trial of Mammosite balloon brachytherapy for partial breast irradiation in early- stage breast cancer. Am J Surg 2007;194:456–62.
36. Gómez-Iturriaga A, Pina L, Cambeiro M, Martínez-Regueira F, Aramendía JM, Fernández-Hidalgo O. Early breast cancer treated with conservative surgery, adjuvant chemotherapy, and delayed accelerated partial breast irradiation with high-dose-rate brachytherapy. Brachytherapy 2008;7:310–5.
37. King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang XZ. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis, 1, 2 breast cancer. Am J Surg 2000;180:299–304.
38. Krishnan L, Jewell WR, Tawfik OW, Krishnan EC. Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer. Breast J 2001;7:91–6.
39. Niehoff P, Polgár C, Ostertag H, Major T, Sulyok Z, Kimmig B, Clinical experience with the MammoSiteÒ radiation therapy system for intracavitary brachytherapy of breast cancer–Results from an iternational phase II trial. Radiother Oncol 2006;79:316–20.
40. Ott OJ, Hildebrandt G, Pötter R, Hammer J, Lotter M, Resch A, Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German– Austrian multi-centre trial. Radiother Oncol 2007;82:281–6.
41. Haffty BG. Molecular and genetic markers in the loco-regional treatment of breast cancer. Semin Radiat Oncol 2002;12:329–40
42. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2013 Nov 8. pii: S0140-6736(13)61950-9. doi: 10.1016/ S0140-6736(13)61950-9. [Epub ahead of print]
43. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial : Lancet Oncol. 2013 Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11
44. Smith BD, Smith BD, Buchholz TA, Kuerer HM: Intraoperative radiotherapy for early breast cancer (correspondence). Lancet 376:1141, 2010
45. Azria D, Lemanski C. Intraoperative radiotherapy for breast cancer. Lancet. 2013 Nov 8. pii: S0140-6736(13)62304-1. doi: 10.1016/S0140-6736(13)62304-1. [Epub ahead of print]
46. Julian TB, Constantino JP, Vicini FA, et al. Early toxicity results with 3D conformal external beam (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. J Clin Oncol. 2011;29(suppl):Abstr S1011.
2. Vicini FA, Arthur DW. Breast brachytherapy: North American experience. Semin Radiat Oncol 2005;15:108–15.
3. Clarke DH, Lé MG, Sarrazin D, Lacombe MJ, Fontaine F, Travagli JP, et al. Analysis of local regional relapses in patients with early breast cancers treated by excision and radiotherapy. Experience of the Institute Gustave Roussy. Int J Radiat Oncol Biol Phys 1985;11:137–45.
4. Van Limbergen E, van der Bogaert W, van der Shueuren E, Rijnders A, et al. Tumor excision and radiotherapy as primary treatment of breast cancer: analysis of patient and treatment parameters and local control. Radiother Oncol 1987;8:1–9.
5. Njeh CF, Saunders MW, Langton CM. Accelerated Partial Breast Irradiation (APBI): A review of available techniques. Radiation Oncology 2010,5:90
6. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology ( ASTRO) Int J Radiat Oncol Biol Phys 2009;74:987-1001.
7. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378–1387.
8. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259–3265.
9. Chao KK, Vicini FA, Wallace M, Mitchell C, Chen P, Ghilezan M, et al. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irra- diation: The William Beaumont hospital experience. Int J Radiat Oncol Biol Phys 2007;69:32–40.
10. Vicini F, Beitsch PD, Quiet CA, Keleher AJ, Garcia D, Snider HC Jr, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 2008;112:758–766.
11. Ribeiro GG, Magee B, Swindell R, Harris M, Banerjee SS.The Christie Hospital breast conservation trial: An update at 8 years from inception. Clin Oncol (R Coll Radiol) 1993;5:278–283.
12. Ribeiro GG, Dunn G, Swindell R, Harris M, Banerjee SS. Conservation of the breast using two different radiotherapy techniques: Interim report of a clinical trial. Clin Oncol (R Coll Radiol) 1990;2:27–34.
13. Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose- rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2006;64:489–495.
14. Kaufman SA, DiPetrillo TA, Price LL, Midle JB, Wazer DE. Long-term out- come and toxicity in a Phase I/II trial using high-dose-rate mul- ticatheter interstitial brachytherapy for T1/T2 breast cancer. Brachytherapy 2007;6:286–292.
15. Evans SB, Kaufman SA, Price LL, Cardarelli G, Dipetrillo TA, Wazer DE. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: Incidence, pathologic anatomy, and contributing factors. Int J Radiat Oncol Biol Phys 2006;65:333–339.
16. Shah NM, Tenenholz T, Arthur D, DiPetrillo T, Bornstein B, Cardarelli G. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: Factors that affect toxicity and cosmesis. Cancer 2004;101: 727–734.
17. Wazer DE, Berle L, Graham R, Chung M, Rothschild J, Graves T, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys 2002;53:889–897.
18. Wazer DE, Lowther D, Boyle T, Ulin K, Neuschatz A, Ruthazer R, et al. Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2001;50:107–111.
19. Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264-73
20. Antonucci JV, Wallace M, Goldstein NS, Kestin L, Chen P, Benitez P, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole- breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 2009;74:447–52.
21. Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95–17. Int J Radiat Oncol Biol Phys 2008;72:467–73.
22. Johansson B, Karlsson L, Liljegren G, Hardell L, Persliden J. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1–T2 breast cancer: first long time results from a clinical study. Radiother Oncol 2009;90:30–5.
23. Patel RR, Christensen ME, Hodge C, Adkison JB, Das RK. Clinical outcome analysis in ‘‘high- risk” versus ”low-risk” patients eligible for National Surgical Adjuvant Breast and Bowel B-39/Radiation Therapy Oncology Group 0413 trial: five-year results. Int J Radiat Oncol Biol Phys 2008;70:970–3.
24. Polgár C, Sulyok Z, Fodor J, Orosz Z, Major T, Takácsi-Nagy Z, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I–II study and initial findings of a randomized phase III trial. J Surg Oncol 2002;80:121–8.
25. Polgár C, Major T, Fodor J, Németh G, Orosz Z, Sulyok Z, et al. HDR brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 2004;60:1173–81.
26. Polgár C, Strnad V, Major T. Brachytherapy for partial breast irradiation: the European experience. Semin Radiat Oncol 2005;15:116–22.
27. Polgár C, Fodor J, Major T, Németh G, Lövey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma – 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007;69:694–702.
28. Polgár C, Major T, Lövey K, et al. Hungarian experience on partial breast irradiation versus whole breast irradiation: 12-year results of a phase II trial and updated results of a randomized study. Brachytherapy 2008;7:91–2 [Abstract].
29. Polgár C, Major T. Current status and perspectives of brachytherapy for breast cancer. Int J Clin Oncol 2009;14:7–24.
30. Strnad V, Ott OJ, Hildebrandt G, et al. Partial breast irradiation using multicatheter interstitial brachytherapy for early breast cancer: Results of the German–Austrian multicenter Phase II trial. Brachytherapy 2009;8:107 [Abstract].
31. Polgár C, Fodor J, Major T, Orosz Z, Németh G. The role of boost irradiation in the conservative treatment of stage I–II breast cancer. Pathol Oncol Res 2001;7:241–50.
32. Polgár C, Fodor J, Orosz Z, Major T, Takácsi-Nagy Z, Mangel LC. Electron and high dose rate brachytherapy boost in the conservative treatment of stage I–II breast cancer: first results of the randomized Budapest boost trial. Strahlenther Onkol 2002;178:615–23.
33. Polgár C, Fodor J, Orosz Z, T Major, Z Sulyok, Z Takacsi-Nagy. Electron and brachytherapy boost in the conservative treatment of stage I–II breast cancer: 5-year results of the randomized Budapest boost trial. Radiother Oncol 2002;64:S15 [Abstract].
34. Clarke DH, Lé MG, Sarrazin D, Lacombe MJ, Fontaine F, Travagli JP, Analysis of local regional relapses in patients with early breast cancers treated by excision and radiotherapy. Experience of the Institute Gustave Roussy. Int J Radiat Oncol Biol Phys 1985;11:137–45
35. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A. Five-year results: the initial clinical trial of Mammosite balloon brachytherapy for partial breast irradiation in early- stage breast cancer. Am J Surg 2007;194:456–62.
36. Gómez-Iturriaga A, Pina L, Cambeiro M, Martínez-Regueira F, Aramendía JM, Fernández-Hidalgo O. Early breast cancer treated with conservative surgery, adjuvant chemotherapy, and delayed accelerated partial breast irradiation with high-dose-rate brachytherapy. Brachytherapy 2008;7:310–5.
37. King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang XZ. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis, 1, 2 breast cancer. Am J Surg 2000;180:299–304.
38. Krishnan L, Jewell WR, Tawfik OW, Krishnan EC. Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer. Breast J 2001;7:91–6.
39. Niehoff P, Polgár C, Ostertag H, Major T, Sulyok Z, Kimmig B, Clinical experience with the MammoSiteÒ radiation therapy system for intracavitary brachytherapy of breast cancer–Results from an iternational phase II trial. Radiother Oncol 2006;79:316–20.
40. Ott OJ, Hildebrandt G, Pötter R, Hammer J, Lotter M, Resch A, Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German– Austrian multi-centre trial. Radiother Oncol 2007;82:281–6.
41. Haffty BG. Molecular and genetic markers in the loco-regional treatment of breast cancer. Semin Radiat Oncol 2002;12:329–40
42. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2013 Nov 8. pii: S0140-6736(13)61950-9. doi: 10.1016/ S0140-6736(13)61950-9. [Epub ahead of print]
43. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial : Lancet Oncol. 2013 Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11
44. Smith BD, Smith BD, Buchholz TA, Kuerer HM: Intraoperative radiotherapy for early breast cancer (correspondence). Lancet 376:1141, 2010
45. Azria D, Lemanski C. Intraoperative radiotherapy for breast cancer. Lancet. 2013 Nov 8. pii: S0140-6736(13)62304-1. doi: 10.1016/S0140-6736(13)62304-1. [Epub ahead of print]
46. Julian TB, Constantino JP, Vicini FA, et al. Early toxicity results with 3D conformal external beam (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. J Clin Oncol. 2011;29(suppl):Abstr S1011.
Downloads
Published
2019-11-06
How to Cite
1.
ศักดิ์ศรชัย ก. Accelerated partial breast irradiation in early breast cancer (APBI). J Thai Assn of Radiat Oncol [Internet]. 2019 Nov. 6 [cited 2024 May 3];20(1):27-41. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/224291
Issue
Section
Review articles
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
